STOCK TITAN
  1. Home
  2. News
  3. BIIB

Biogen Inc - BIIB STOCK NEWS

Welcome to our dedicated news page for Biogen (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biogen's position in the market.

News
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
Rhea-AI Summary
Biogen receives a positive CHMP opinion for TOFIDENCE™, a biosimilar referencing ROACTEMRA®. The CHMP's positive opinion is based on robust analytical, non-clinical, and clinical data comparing TOFIDENCE™ to ROACTEMRA®. If granted marketing authorization by the EC, TOFIDENCE™ will be used to treat rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. Biogen's biosimilars portfolio in Europe may see an addition of TOFIDENCE™, offering cost-effective treatment options with a new mechanism of action. The recommendation signifies a step towards providing more patients with high-quality biologic medicines. The positive opinion was supported by analytical, non-clinical, and clinical data, confirming TOFIDENCE™ as a biosimilar to the reference product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Rhea-AI Summary
Eisai and Biogen submit a sBLA for LEQEMBI maintenance dosing for Alzheimer's disease treatment. Fast Track designation sought for SC formulation. LEQEMBI aims to reduce protofibrils' impact on brain injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
News
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
Rhea-AI Summary
AbCellera (ABCL) partners with Biogen Inc. (BIIB) to discover antibodies for brain-targeted biotherapeutics in neuroscience. The collaboration aims to address the challenge of delivering biologics across the blood-brain barrier. AbCellera will receive upfront payment, milestone payments, and potential royalties on future product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
none
News
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Rhea-AI Summary
Biogen Inc. announced positive interim 6-month biomarker data from the open-label RESPOND study, showing reductions in neurofilament levels in most participants treated with SPINRAZA. The Phase 4 study focuses on infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after Zolgensma treatment. The data indicate improvements in motor function and reductions in neurodegeneration, highlighting the potential benefits of SPINRAZA in maximizing patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
Rhea-AI Summary
Biogen Inc. to present new data on Alzheimer's disease portfolio at AD/PD™ 2024 conference, showcasing advancements in tau aggregation inhibition and disease progression understanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
-
News
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Rhea-AI Summary
Biogen receives positive opinion from CHMP for QALSODY® (tofersen) for the treatment of SOD1-ALS, marking a significant milestone in ALS treatment with potential to target genetic causes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
News
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Rhea-AI Summary
Biogen's SKYCLARYS (omaveloxolone) receives European Commission approval for treating Friedreich’s ataxia, marking a significant advancement in rare disease treatment. The groundbreaking therapy demonstrated improved patient function in clinical trials, offering hope for patients with this debilitating condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
none
-
News
Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
Rhea-AI Summary
Aptar Digital Health, a part of AptarGroup, Inc., has entered into an enterprise agreement with Biogen Inc. to develop digital health solutions for neurological and rare diseases globally. The collaboration will cover several indications in neurology and immunology across 15 countries, focusing on providing advanced digital solutions for disease management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.18%
Tags
none
-
News
Biogen to Realign Resources for Alzheimer's Disease Franchise
Rhea-AI Summary
Biogen Inc. announces plans to reprioritize resources in Alzheimer's disease, focusing on advancing LEQEMBI and developing new treatment modalities. The company will discontinue the development of ADUHELM and terminate the ENVISION clinical study, with no safety or efficacy concerns. Biogen will accelerate the development of potential new treatment modalities, including ASO targeting tau and an oral small molecule inhibitor of tau aggregation. The decision is part of a strategic review to prioritize the company's portfolio and will result in a one-time charge of approximately $60 million related to close out costs for the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
News
Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)
Rhea-AI Summary
Alcyone Therapeutics Inc. (Alcyone) announced the first patient implanted in the PIERRE pivotal study to evaluate the safety and performance of the ThecaFlex DRx System (ThecaFlex) subcutaneous port and intrathecal catheter system for repeat intrathecal access, cerebrospinal fluid (CSF) aspiration, and delivery of SPINRAZA® (nusinersen) in spinal muscular atrophy (SMA) patients. The ThecaFlex device has the potential to significantly benefit patients with SMA who are being treated with SPINRAZA and are resistant to lumbar punctures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
clinical trial
Stock BIIB logo
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

#391 Ranked by Market Cap
#3170 Ranked by Stock Gains
N/A Ranked by Dividends

BIIB Stock Data

28.37B
144.82M
0.69%
92.98%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili